EE377 Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain

Autor: Peral, C 1, Azanza, JR 2, Gonzalez del Castillo, JM 3, Ferrando, R 4, Molero Garcia, JM 5, Soriano, A 6, Ariznavarreta Martin, A 7, Garí, C 8, De Lossada Juste, A 1, López Gómez, V 1
Zdroj: In Value in Health December 2024 27(12) Supplement:S129-S129
Databáze: ScienceDirect
Externí odkaz: